The Use Of Inotropic Vasodilators In Transthyretin Amyloid Patients Presenting With Cardiogenic Shock: Descriptive Case Series
Maria Riasat,Alaa M. Omar,Darren Kong,Errol Moras,Kruti Gandhi,Cathleen Varley,Sean Pinney,Ashish Correa,Johanna Contreras,Kiran Mahmood,Arieh Fox
DOI: https://doi.org/10.1016/j.cardfail.2023.10.351
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Background Transthyretin amyloid cardiomyopathy (ATTR-CM) carries a grave prognosis compared to other causes of cardiomyopathy. There is sparse data regarding the use and clinical effect of inotropic vasodilators (inodilators) among patients with ATTR-CM presenting with cardiogenic shock. Methods We present a series of 28 ATTR-CM patients hospitalized (78.5±8.4 years, 32% women, EF: 36.4±12.6%) with cardiogenic shock needing inodilators (22 on milrinone, and 6 on dobutamine). Results Inodilators were started in 19(%) patients for stage C/D cardiogenic shock, 8 for stage B cardiogenic shock, and 1 for palliation. The median hospital length of stay was 13 days, and the median cardiac care unit (CCU) stay was 6.5 days. Regarding baseline medications, 18(64%) patients were on tafamidis, 19(68%) were on at least one guideline-directed medical therapy [ GDMT: angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs), sacubitril/valsartan (ARNI) therapy, beta-blockers (BB), mineralocorticoid antagonist (MRA), or sodium-glucose co-transporter-2 inhibitors (SGLT2i), table 1], and 2 patients were on RNAi drugs. In 18 patients, shock deteriorated necessitating the use of vasopressors (norepinephrine, epinephrine, vasopressin, or phenylephrine). 11 patients died during the hospitalization, of these 3 patients died in the cardiac critical care unit (CCU), and 17 patients were discharged who were followed for a median of 7 months during which 4 patients died and 11 had heart failure hospitalization. Compared to before the start of inotropes, mean arterial blood pressure (MAP) significantly increased at the stopping of the inotropes (70.8±12.6 vs. 83.6±16 mmHg, p<0.001), however, there were no differences for creatinine, brain natriuretic peptide (BNP), troponin, or cardiac index. Compared to patients who were discharged, patients who died in the hospital were not different regarding age, sex, GDMT, tafamidis or RNAi therapy, cardiogenic shock stage, baseline MAP, creatinine, BNP, troponin, lactate, cardiac index, or the use of vasopressors, however patients who died had significantly lower LVEF (31.5±14 vs. 42.6±13%, p=0.045). Similar findings were noted using overall mortality or combined events were used to classify patients. Conclusion In this case series, we described the use of inodilators among patients with advanced heart failure due to ATTR-CM presenting in different stages of cardiogenic shock. The findings of this case series suggest that ATTR-CM presenting with cardiogenic shock is typically rapidly fatal despite the use of inodilators, especially with lower LV systolic function.
cardiac & cardiovascular systems